Macular Telangiectasia: Protecting Your Central Vision
Understanding Macular Telangiectasia
Macular telangiectasia is a condition that damages the macula, the small area at the center of the retina responsible for detailed vision. The disease involves abnormal changes to the tiny blood vessels, called capillaries, that surround the fovea. The fovea is the very center of the macula and provides the sharpest vision.
In MacTel, these capillaries become irregular. Depending on the type, they may widen, leak fluid, or contribute to the breakdown of important retinal cells. This leads to gradual loss of central vision over many years.
There are two main types of macular telangiectasia, and they behave quite differently. Type 1 MacTel involves widened blood vessels and tiny bulges called aneurysms that leak fluid. This leaking causes macular edema, or swelling of the macula, which damages delicate cells. Type 1 almost always affects only one eye.
Type 2 MacTel is more common and typically affects both eyes. It occurs most often in middle-aged adults, and men and women are affected equally. Rather than being primarily a blood vessel disease, Type 2 MacTel is now understood to be a degenerative condition driven by the loss of supportive cells in the retina.
In Type 2 MacTel, the damage starts with the breakdown of Muller cells. These are glial cells, a type of support cell, that surround and nourish neurons in the retina. When Muller cells deteriorate, the outer layers of the retina begin to thin. This thinning leads to the loss of photoreceptors, the specialized cells that detect light and send visual signals to the brain.
As the disease progresses, the retina may develop small cavity-like spaces across its layers. In advanced stages, a full-thickness macular hole can form. Some patients also develop macular neovascularization, meaning new, abnormal blood vessels grow beneath the retina. These fragile vessels can leak fluid or bleed, causing further damage to central vision.
Who Is Affected and Risk Factors
Macular telangiectasia Type 2 is uncommon. Studies estimate its prevalence at about 0.1% in people aged 43 to 86 years (Beaver Dam Eye Study, PMC). The incidence of new cases in one U.S. study was approximately 0.0008% per year in Olmsted County, Minnesota, adjusted for the age and sex of the 2010 U.S. Census Caucasian population (Healio Ophthalmic Surgery, Lasers and Imaging Retina, 2020). International studies have reported prevalence rates of 0.06% in Kenya and Nigeria, and 0.0045% to 0.022% in Melbourne, Australia (Ophthalmic Epidemiology, 2012).
The average age at diagnosis is around 63 years, according to the Beaver Dam Eye Study. Both men and women develop Type 2 MacTel at similar rates.
The exact cause of MacTel remains unknown. However, research has identified several conditions that appear more often in people with MacTel Type 2. These include:
- Type 2 diabetes
- High cholesterol, also called hyperlipidemia
- High triglycerides, also called hypertriglyceridemia
- Hypertension, or high blood pressure
Studies have found that people with MacTel Type 2 are significantly more likely to have type 2 diabetes and elevated blood lipid levels compared to the general population (Beaver Dam Eye Study, PMC). If you have any of these conditions, discussing retinal screening with your eye care provider may be worthwhile.
Research into the genetic basis of MacTel is ongoing. While no single gene has been identified as the definitive cause, some evidence suggests that genetic factors may play a role. Families with more than one affected member have been reported. However, most cases appear to occur without a clear family pattern.
Signs and Symptoms
In its earliest stages, macular telangiectasia produces no noticeable symptoms. Many people are unaware they have the condition until it is detected during a routine eye exam. The disease can be present for years before any visual changes are felt.
One of the earliest clinical signs is a blunting of the foveal reflex, a subtle change that a retina specialist can detect during an eye examination. At this stage, standard vision tests may still show good results.
Over time, MacTel causes a slow decline in central vision. Common symptoms include:
- Blurring of central vision
- Distorted vision, known as metamorphopsia, where straight lines may appear wavy or bent
- Scotomas, or blind spots, in the central visual field
- Needing brighter light to read or perform close-up tasks
- Difficulty with activities that require fine detail, such as reading or threading a needle
Many patients with MacTel report significant visual difficulties even when they perform reasonably well on standard eye chart tests. The loss of central vision typically progresses over a period of 10 to 20 years. Some patients remain stable for many years with little noticeable change, while others experience gradual worsening.
In most cases, MacTel progresses slowly. However, rapid vision loss can occur if macular neovascularization develops. When abnormal blood vessels grow beneath the retina, they may leak fluid or bleed. This can cause a sudden or noticeable decline in vision. If you experience a sudden change in your central vision, see a retina specialist or go to the emergency room immediately.
Diagnosis and Testing
Macular telangiectasia can be difficult to diagnose because its early signs are subtle. A retina specialist uses several imaging tools to identify the condition and track its progression. A comprehensive dilated eye exam is the starting point, during which the specialist examines the macula for characteristic changes in the blood vessels and retinal tissue.
Optical coherence tomography, commonly called OCT, is one of the most important tools for diagnosing MacTel. OCT creates detailed cross-sectional images of the retina, revealing thinning, cavity-like spaces, and loss of the outer retinal layers. These findings are hallmarks of Type 2 MacTel.
Other tests a retina specialist may use include:
- Fluorescein angiography, a test in which dye is injected into a vein in the arm and photographs are taken as the dye passes through the retinal blood vessels, highlighting areas of leakage or abnormal vessels
- OCT angiography, a newer noninvasive imaging technique that maps blood flow in the retina without the need for injected dye
- Fundus photography, which captures detailed images of the back of the eye
Several other retinal conditions can mimic the appearance or symptoms of MacTel. These include diabetic macular edema, age-related macular degeneration, and macular holes. A retina specialist uses the combination of clinical findings and imaging results to distinguish MacTel from these other conditions. The bilateral nature of Type 2 MacTel and the characteristic pattern of retinal thinning on OCT are important distinguishing features.
Treatment Options
Encelto (revakinagene taroretcel-lwey) became the first FDA-approved treatment for macular telangiectasia Type 2 on March 6, 2025. This cell therapy works by slowing the loss of macular photoreceptors. Encelto uses encapsulated cell therapy technology. A tiny implant, about the size of a grain of rice, is surgically placed in the eye. The implant contains living cells that have been genetically modified to continuously produce and release a protein called ciliary neurotrophic factor, or CNTF. CNTF is a neuroprotective agent that helps protect photoreceptors from degeneration.
The approval was supported by positive results from two phase 3 clinical trials. In Protocol A, treated patients experienced a 56.4% reduction in the rate of photoreceptor loss compared to untreated patients over 24 months. In Protocol B, the reduction was 29.2% (Neurotech Pharmaceuticals, 2025). Encelto became available in the United States in 2025.
When MacTel leads to macular neovascularization, meaning abnormal blood vessels have formed beneath the retina, treatment with anti-VEGF injections is the standard approach. Anti-VEGF stands for anti-vascular endothelial growth factor. These medications block a chemical signal that drives abnormal blood vessel growth.
Common anti-VEGF medications used for this complication include:
- Eylea (aflibercept), typically given every 4 to 8 weeks after an initial loading phase
- Lucentis (ranibizumab), typically given every 4 weeks
- Avastin (bevacizumab), which is FDA-approved for cancer and used off-label for eye conditions, typically given every 4 to 6 weeks
- Vabysmo (faricimab), a bispecific antibody that may be given every 4 to 16 weeks
These injections are given directly into the eye by a retina specialist. They help reduce the growth of abnormal blood vessels, slow leakage, and reduce swelling in the macula. Not all patients with MacTel develop neovascularization, so anti-VEGF treatment is reserved for those who do.
For many patients with MacTel Type 2, especially those in the early stages without neovascularization, close monitoring by a retina specialist is the primary approach. Regular eye exams with OCT imaging allow the specialist to track changes in retinal structure and detect any progression. If neovascularization develops or the condition worsens, treatment can be started promptly.
What to Expect
Macular telangiectasia Type 2 is a slowly progressive condition. Most patients experience a gradual decline in central vision over 10 to 20 years. The rate of progression varies considerably from person to person. Some patients remain relatively stable for long periods, while others notice a steady worsening of their ability to read, recognize faces, or see fine details.
Peripheral vision, the side vision you use to navigate and move around, is typically preserved. This means that even with advanced MacTel, most patients do not experience total blindness.
For patients who receive Encelto, the implant is placed during a surgical procedure by a retina specialist. After the surgery, regular follow-up visits are needed to monitor the implant and assess the health of the retina. The implant is designed to continuously deliver CNTF without the need for repeated injections, which may reduce the overall treatment burden over time.
As with any eye surgery, there are potential risks. A retina specialist will discuss these risks and benefits before recommending the procedure.
If macular neovascularization develops, anti-VEGF injections may be needed on an ongoing basis. The injection process is performed in the office of a retina specialist. Numbing drops are applied to the eye before the injection. Most patients report feeling pressure rather than sharp pain, although some discomfort is common. After each injection, mild soreness, redness, or the sensation of something in the eye may last for a day or two.
Living With Macular Telangiectasia
Because MacTel affects central vision, everyday tasks that require sharp focus can become more challenging over time. Many patients benefit from practical adjustments such as using magnifying glasses, increasing the font size on electronic devices, using audiobooks, and improving lighting at home and at work.
Low vision rehabilitation services can help patients learn new strategies to make the most of their remaining vision. A retina specialist or optometrist can provide a referral to a low vision specialist.
Patients with MacTel can monitor their own vision between appointments. One useful tool is the Amsler grid, a simple chart with a grid of straight lines and a central dot. Looking at the grid one eye at a time, you can check for new distortions, blank spots, or wavy lines. Any new changes should be reported to your retina specialist promptly.
A diagnosis of a progressive eye condition can be stressful. It is normal to feel anxious or frustrated about potential changes to your vision. Support groups, counseling, and connecting with other patients who have MacTel can be helpful. Organizations such as the Foundation Fighting Blindness and BrightFocus Foundation provide educational resources and community connections for people with retinal diseases.
When to See a Retina Specialist
Because MacTel can be present for years without symptoms, routine comprehensive eye exams are important, especially for adults over the age of 40. If you have risk factors such as diabetes, high cholesterol, or high blood pressure, mention these to your eye care provider. Early detection through OCT and other imaging allows for timely monitoring and intervention if the disease progresses.
While MacTel usually progresses slowly, certain symptoms require immediate attention. See a retina specialist or go to the emergency room right away if you experience any of the following:
- A sudden increase in floaters, the tiny specks or threads that drift across your vision
- Flashes of light in your vision
- A curtain or shadow appearing over part of your visual field
- Sudden loss of vision in one eye
These symptoms could indicate a serious complication, such as bleeding from neovascularization or a retinal detachment. Prompt evaluation is critical to protecting your vision.
Questions and Answers
Yes. A retina specialist can often detect early signs of MacTel during a dilated eye exam, even before you notice any changes in your vision. Optical coherence tomography is particularly useful for identifying the subtle retinal thinning and structural changes that characterize the condition in its earliest stages. This is one reason regular eye exams are valuable, especially as you age.
Macular telangiectasia affects central vision, not peripheral vision. While central vision may decline over many years, most patients retain enough side vision to navigate their environment, move around safely, and maintain independence. The pace of vision loss varies widely. Some patients experience very slow changes, while others may notice a more noticeable decline over time. With monitoring and appropriate treatment, the impact on daily life can often be managed.
Encelto (revakinagene taroretcel-lwey) is designed to be placed once during a surgical procedure. The implant continuously releases ciliary neurotrophic factor to help protect photoreceptors from degeneration. While the implant is intended to provide ongoing benefit without repeated injections, regular follow-up visits with a retina specialist are needed to monitor its function and the health of your retina. Discuss the long-term expectations and any potential need for additional procedures with your specialist.
Diabetes is a recognized risk factor for MacTel Type 2. If you have type 2 diabetes, it is important to have regular comprehensive eye exams that include retinal imaging. While diabetic eye disease, such as diabetic retinopathy and diabetic macular edema, is more common, your retina specialist can also evaluate for signs of MacTel during these visits. Mention any changes in your central vision, such as new blurring, distortion, or difficulty reading, to your provider.
There are no proven lifestyle interventions that directly slow the progression of macular telangiectasia. However, managing conditions associated with MacTel, such as diabetes, high blood pressure, and high cholesterol, is important for overall eye health. Maintaining a healthy diet, exercising regularly, not smoking, and controlling blood sugar and blood pressure may support retinal health in general. Follow the guidance of both your primary care doctor and your retina specialist for the best overall approach.